Celldex Therapeutics CLDX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's total liabilities & equity?
- Celldex Therapeutics (CLDX) reported total liabilities & equity of $511.25M in Q1 2026.
- How has Celldex Therapeutics's total liabilities & equity changed year-over-year?
- Celldex Therapeutics's total liabilities & equity decreased by 30.9% year-over-year, from $739.47M to $511.25M.
- What is the long-term trend for Celldex Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Celldex Therapeutics's total liabilities & equity has grown at a 19.8% compound annual growth rate (CAGR), from $235.84M to $582.98M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.